TY - JOUR
T1 - Recent Use of Synthetic Cannabinoids, Synthetic Opioids, and Other Psychoactive Drug Groups among High-risk Drug Users
AU - Shapira, Barak
AU - Berkovitz, Ronny
AU - Rosca, Paola
AU - Neumark, Yehuda
N1 - Publisher Copyright:
© 2020 Taylor & Francis Group, LLC.
PY - 2020/8/7
Y1 - 2020/8/7
N2 - The use of synthetic cannabinoids receptor agonists (SCRA) and synthetic opioids is associated with significant morbidity and mortality. This study examined the patterns-of-use of prescription oral opioids or transdermal fentanyl formulations, and SCRA, among 342 patients enrolled in treatment for drug-dependence in Israel. 16.1% of participants reported recent (past-12 months) SCRA use, while 24.9% reported recent use of prescription oral opioids, transdermal fentanyl patches, or both. Odds of reporting recent use of SCRA were positively and significantly associated with reporting recent use of cannabis (Adjusted Odds Ratio [AOR] 9.86, 95% Confidence Interval [CI] 4.44–21.90) and synthetic cathinones (AOR 5.47, CI 2.50–11.96). Recent use of prescription oral opioids or transdermal fentanyl formulations use was positively and significantly associated with recent use of gabapentinoids (AOR 14.33, CI 7.10, 28.90), stimulants (AOR 7.12, CI 3.82,13.28), heroin (AOR 5.81, CI 3.39,9.97), benzodiazepines (AOR 4.63, CI 2.74,7.84), synthetic cathinones (AOR 4.12, CI 1.95, 8.70), and hallucinogens (AOR 2.48, CI 1.24, 2.96). Clinicians should be informed about the extent of prescription oral opioids or transdermal fentanyl formulations and SCRA use among high-risk drug users, and the associated higher odds of concomitantly using other psychoactive substance, for they represent actual risk to patients and complicate treatment.
AB - The use of synthetic cannabinoids receptor agonists (SCRA) and synthetic opioids is associated with significant morbidity and mortality. This study examined the patterns-of-use of prescription oral opioids or transdermal fentanyl formulations, and SCRA, among 342 patients enrolled in treatment for drug-dependence in Israel. 16.1% of participants reported recent (past-12 months) SCRA use, while 24.9% reported recent use of prescription oral opioids, transdermal fentanyl patches, or both. Odds of reporting recent use of SCRA were positively and significantly associated with reporting recent use of cannabis (Adjusted Odds Ratio [AOR] 9.86, 95% Confidence Interval [CI] 4.44–21.90) and synthetic cathinones (AOR 5.47, CI 2.50–11.96). Recent use of prescription oral opioids or transdermal fentanyl formulations use was positively and significantly associated with recent use of gabapentinoids (AOR 14.33, CI 7.10, 28.90), stimulants (AOR 7.12, CI 3.82,13.28), heroin (AOR 5.81, CI 3.39,9.97), benzodiazepines (AOR 4.63, CI 2.74,7.84), synthetic cathinones (AOR 4.12, CI 1.95, 8.70), and hallucinogens (AOR 2.48, CI 1.24, 2.96). Clinicians should be informed about the extent of prescription oral opioids or transdermal fentanyl formulations and SCRA use among high-risk drug users, and the associated higher odds of concomitantly using other psychoactive substance, for they represent actual risk to patients and complicate treatment.
KW - Prescription opioids
KW - cannabinoids
KW - drug substitution
KW - prevalence
UR - http://www.scopus.com/inward/record.url?scp=85084250290&partnerID=8YFLogxK
U2 - 10.1080/02791072.2020.1754534
DO - 10.1080/02791072.2020.1754534
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32345134
AN - SCOPUS:85084250290
SN - 0279-1072
VL - 52
SP - 334
EP - 343
JO - Journal of Psychoactive Drugs
JF - Journal of Psychoactive Drugs
IS - 4
ER -